KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero Yuseong-gu, Daejeon 34054, Republic of Korea.
KM Convergence Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero Yuseong-gu, Daejeon 34054, Republic of Korea.
Life Sci. 2023 Jun 15;323:121700. doi: 10.1016/j.lfs.2023.121700. Epub 2023 Apr 15.
Compound K (CK) is a secondary ginsenoside biotransformed from ginseng. This review discusses the function of CK as a potential ligand of the glucocorticoid receptor and a regulator of macrophage inflammatory responses. We provide findings on the ability of CK to inhibit the activation of M1 macrophages and promote the activation and differentiation of M2 macrophages. In addition, the effect of inhibiting the inflammasome response was collected. We summarized the evidences that CK is effective in the treatment of various inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, dermatitis, asthma, chronic obstructive pulmonary disease, sepsis associated encephalopathy, atherosclerosis, inflammatory bowel disease, and diabetes. These findings suggest the potential of CK as a therapeutic agent that can resolve inflammation and restore homeostasis.
化合物 K（CK）是一种由人参转化而来的次级人参皂苷。本综述讨论了 CK 作为糖皮质激素受体潜在配体和调节巨噬细胞炎症反应的功能。我们提供了 CK 抑制 M1 巨噬细胞活化并促进 M2 巨噬细胞活化和分化的能力的研究结果。此外，还收集了抑制炎症小体反应的效果。我们总结了 CK 可有效治疗各种炎症性疾病的证据，如类风湿关节炎、系统性红斑狼疮、皮炎、哮喘、慢性阻塞性肺疾病、脓毒症相关脑病、动脉粥样硬化、炎症性肠病和糖尿病。这些发现表明 CK 具有作为一种治疗剂的潜力，它可以解决炎症并恢复体内平衡。
